SS-31 30mg Dosage Protocol | PeptideDosages.com

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SS-31 (30 mg Vial) Dosage Protocol

SS-31 Dosage Chart

SS-31 is dosed at 5 mg–10 mg daily via subcutaneous injection in educational protocols. A 30 mg vial reconstituted with bacteriostatic water yields about 10 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~10 mg/mL concentration for convenient dosing.

Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.

Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome[3]. This educational protocol presents a once‑daily subcutaneous approach using the 30 mg vial format with practical reconstitution for insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read SS-31 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3.0 mL = ~10 mg/mL)

Weeks 1–2

5 mg (5000 mcg)

50 units (0.50 mL)

Weeks 3–8

10 mg (10,000 mcg)

100 units (1.0 mL)

Frequency: Inject once daily subcutaneously at a consistent time. This 30 mg vial reconstituted with 3.0 mL keeps standard doses within a single insulin syringe for convenience and accuracy.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.

Gently swirl/roll until fully dissolved (clear solution).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

Advanced / Aggressive Approach (3.0 mL = ~10 mg/mL)

Weeks 3–4

Weeks 5–8

15 mg (15,000 mcg)

Split: 2 × 75 units (0.75 mL each)

Optional Weeks 9–12

20 mg (20,000 mcg)

Split: 2 × 100 units (1.0 mL each)

Note: Advanced dosing (15–20 mg/day) is based on short‑term clinical trial protocols[4][5] for severe mitochondrial conditions and should only be pursued under medical supervision. Doses above 10 mg require splitting into two separate subcutaneous injections at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration using 30 mg vials.

Peptide Vials (SS‑31, 30 mg each):

8 weeks (Standard: 5–10 mg/day) ≈ 17 vials

12 weeks (Standard maintenance at 10 mg/day) ≈ 26 vials

12 weeks (Advanced: escalating to 15 mg/day) ≈ 35 vials

Insulin Syringes (U‑100, 1 mL capacity):

Per week (standard dosing): 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

Advanced protocols with split injections may require 2 syringes per day for higher doses

Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (17 vials): 51 mL → 2 × 30 mL bottles

12 weeks (26 vials): 78 mL → 3 × 30 mL bottles

12 weeks (35 vials, advanced): 105 mL → 4 × 30 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

02AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

03Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

05P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

Research context

Read sources and limitations before applying a claim.

What the Evidence Actually Shows, and at What Level of Confidence

Separating mechanism from proof is the single most important discipline in reading this literature. The mechanistic case is strong and internally consistent. The clinical case is early, small, and deliberately modest in what it claims. Here it is worth being explicit about the hierarchy of evidence, from weakest to strongest: cell-culture experiments, animal models, uncontrolled human observations, small randomized safety trials, and finally large randomized efficacy trials with disease-relevant endpoints. NAD+ in Parkinson’s disease currently has a great deal at the lower rungs and very little at the top.1 At the preclinical level, NAD+ precursors have shown protective effects across multiple Parkinson’s models. Boosting NAD+ has improved mitochondrial function, reduced alpha-synuclein toxicity, and extended survival in fruit-fly and rodent systems, and the 2025 UPRmt/mitophagy work provided a specific mechanistic account of one way this protection might occur.1,5,6 These are meaningful signals, but animal models of Parkinson’s disease are notoriously imperfect predictors of human benefit; the graveyard of neuroprotective agents that worked in mice and failed in people is large. Preclinical success is a reason to run a human trial, not a substitute for one. The most important human data come from a small set of Norwegian trials. The NADPARK study, published in Cell Metabolism in 2022, was a randomized, double-blind, placebo-controlled phase I trial in 30 newly diagnosed, treatment-naive patients who received 1,000 mg of oral nicotinamide riboside or placebo for 30 days.1 Its purpose was to establish safety and target engagement. It succeeded on both counts: NR was well tolerated and produced a significant, though variable, increase in cerebral NAD+ measured by phosphorus magnetic resonance spectroscopy, alongside changes in related metabolites in cerebrospinal fluid. In the subgroup whose brain NAD+ actually rose (the responders), the investigators observed altered cerebral metabolism on FDG-PET and reported an associated mild clinical improvement, and blood and muscle transcriptomics showed upregulation of mitochondrial, lysosomal, and proteasomal gene programs.1 These are encouraging exploratory findings. They are not proof of efficacy: the trial was not powered or designed to demonstrate a change in disease progression, the clinical signal was in a post-hoc responder subgroup, and 30 days is a fraction of the timescale over which Parkinson’s disease evolves. The follow-up NR-SAFE trial, published in Nature Communications in 2023, tested a much higher dose, 3,000 mg of NR daily (1,500 mg twice daily), against placebo for four weeks in 20 patients, again primarily to assess safety.2 All 20 participants completed the study. There were 42 adverse events in total, 25 in the NR group and 17 in the placebo group, and critically all were graded mild, with no moderate or severe events and no statistically significant difference in adverse-event frequency between arms. No painful flushing was reported. The NR group showed a statistically significant improvement in total MDS-UPDRS score (from 51.0 to 40.3, p = 0.007) while placebo did not, but the authors themselves flagged this as preliminary and potentially confounded, including by differences in the timing of levodopa dosing relative to assessment.2 A responsible reading treats NR-SAFE as reassuring on high-dose safety and hypothesis-generating on efficacy, nothing more. The decisive test is the NOPARK study (NCT03568968), a phase III randomized, double-blind, placebo-controlled trial of 1,000 mg oral NR daily over 52 weeks in roughly 400 patients with early Parkinson’s disease across multiple Norwegian centers, with the change in total MDS-UPDRS as its primary endpoint.3 This is the appropriately sized, appropriately long, efficacy-focused trial the field needs. As of this writing the trial has completed enrollment and follow-up, but its primary clinical results have not been published, so no conclusion about efficacy can be drawn. Until those results appear, the honest evidence level for “NAD+ precursors slow Parkinson’s progression” is: plausible mechanism, safe in the short term at the doses tested, and unproven in humans. Alongside these interventional data sit epidemiological signals that are hypothesis-supporting but causally weak, discussed in the next section.

Source: dosagepeptide.com ↗

Handling and Reconstitution in a Research Context

Because AOD-9604 is most often encountered as a lyophilized (freeze-dried) powder in a sealed vial, a brief, strictly educational note on laboratory handling is warranted — with the emphasis that this is standard research-peptide practice, not a usage recommendation, and that AOD-9604 is not an approved therapeutic for any indication. Lyophilized peptides are generally reconstituted with sterile or bacteriostatic water for laboratory purposes. The diluent is directed slowly against the inside wall of the vial rather than sprayed onto the powder, and the vial is gently swirled rather than shaken, because vigorous agitation can shear peptide bonds and denature the material. The volume of diluent chosen simply sets the concentration: a fixed mass of peptide dissolved in a larger volume yields a lower concentration per unit volume, the arithmetic underlying any reconstitution chart. Standard stability and storage considerations recur across the research-peptide literature. Lyophilized storage Cool, dark conditions; long-term stability favored by freezing After reconstitution Refrigerated; used within a limited window Light and heat Minimize exposure; both can degrade peptides Agitation Swirl gently; avoid shaking or foaming Freeze-thaw Repeated cycles degrade peptides; avoid Sterility Aseptic technique; bacteriostatic water for multi-use practice It bears repeating that meticulous handling changes nothing about the evidence question. A perfectly reconstituted, high-purity vial of AOD-9604 is still a compound whose antilipogenic action is documented only preclinically and never quantified in humans. Good technique preserves whatever biological activity the molecule has; it does not create efficacy where none has been demonstrated. Researchers surveying how these compounds are cataloged can consult the site’s central dosages index, organized for educational reference rather than as guidance for human use.

Source: dosagepeptide.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗

Dosage reference

SNAP-8 Dosage Chart for a 10 mg Vial

SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research. Best documented conventional cream reference: About 0.005% active SNAP-8, equal to 50 ppm. Developer reference range: About 0.0015% to 0.005% active peptide in the finished topical formula. Whole 10 mg vial at 0.005%: 200 g final batch weight. 50 g batch at 0.005%: 2.5 mg active peptide. Human schedule context: Twice-daily cream application for 28 days in manufacturer testing. The widely quoted 3% to 10% use level refers to a supplier solution containing about 0.05% SNAP-8. It equals roughly 0.0015% to 0.005% active peptide in the finished formula, not 3% to 10% pure peptide[4][6]. Research context: For identity, mechanisms, human findings, limitations, and safety, read SNAP-8 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Source: peptidedosages.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

SS-31 (30 mg Vial) Dosage Protocol

SS-31 Dosage Chart

Standard / Gradual Approach (3.0 mL = ~10 mg/mL)

Reconstitution Steps

Advanced / Aggressive Approach (3.0 mL = ~10 mg/mL)

Supplies Needed

Related questions

What the Evidence Actually Shows, and at What Level of Confidence

Handling and Reconstitution in a Research Context

How to convert mcg to mg (and back)

SNAP-8 Dosage Chart for a 10 mg Vial

Peptide Therapy Guide Editorial Team

Vilon Dosage Protocol | PeptideDosages.com

Vesugen Dosage Protocol | PeptideDosages.com

Testagen Dosage Protocol | PeptideDosages.com

SS-31 10mg Dosage Protocol | PeptideDosages.com